B
BiPar Sciences
Pharmacological company developing parp inhibitors as cancer therapies
About BiPar Sciences
BiPar Sciences is a unique student recruitment agency founded by doctors who have personally experienced studying medicine abroad. The company specializes in guiding prospective medical students through the complex application process, leveraging firsthand knowledge and experience to offer tailored support. BiPar Sciences serves aspiring medical students who seek to study abroad, primarily focusing on European and Indian markets. The business operates on a consultancy model, earning revenue through service fees charged to students for application assistance, advisory services, and placement support. By providing expert guidance and personalized services, BiPar Sciences aims to simplify the application process and improve the chances of acceptance for its clients. The company stands out due to its deep understanding of the challenges faced by international medical students and its commitment to student-centric service.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2002
- Headquarters
- Brisbane, Australia
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 58.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Apr 2009 | $500M | $500M | Sanofi Aventis | — |
| SERIES COther financing | Jan 2009 | $20M | $80M | PolyTechnos Venture Partners · Canaan · Quantum Technology Partners · Asset Management Ventures | — |
Growth signals
Latest recorded traffic for BiPar Sciences is 110 monthly website visits. BiPar Sciences's team declined 12.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Cercano Management
Canaan- QPQuantum Technology Partners
PolyTechnos Venture Partners
Asset Management Ventures
Domain Associates
Sand Hill Angels
Series B and later1 investor entered at this stage
Lighthouse Capital Partners
Other known investors2 additional known investors
Sanofi Aventis
University of California, San Francisco
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about BiPar Sciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BiPar Sciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.